Intravaginal ring providing dual protection is first of its kind to enter a clinical trial
Women’s reproductive health may never be the same, thanks to Northwestern University biomedical engineer Patrick Kiser and his first-of-its-kind intravaginal ring that reliably delivers an antiretroviral drug and a contraceptive for months.
Kiser’s one ring delivers two drugs that do three important things: the device is designed to protect against HIV and herpes as well as unwanted pregnancy. It will be the first device with the potential to offer this protection to be tested in women.
The easy-to-use ring delivers controlled doses of tenofovir (a common antiretroviral drug) and levonorgestrel (a contraceptive) for 90 days. The rings are being manufactured now, and the device soon will undergo its first test in women.
Details of the development of the ring, a device that represents a lot of ‘firsts,’ was published March 5 by PLOS ONE, a peer-reviewed, open-access online journal.
According to the World Health Organization, 35 million people around the world live with HIV, and 222 million women would like to delay or stop childbearing but are not using any method of contraception.
“I suspect women will use the ring primarily for contraception, but they also will benefit from protection against sexually transmitted diseases,” said Kiser, an expert in intravaginal drug delivery. “And for women in the developing world in particular, unwanted pregnancy can have significant health, economic and cultural consequences. We want to motivate women to use this ring.”
The ring, 5.5 centimeters in diameter, is simple yet complex. Kiser and his colleagues worked painstakingly for five years, engineering the three materials that make up the ring and optimizing the device to reliably deliver fixed and efficacious doses of two medicines over a long period of time.
“A lot of engineering has gone into developing the ring,” said Kiser, senior author of the paper. “It represents two Ph.D. theses — one Ph.D. for the larger section containing the antiretroviral drug and another Ph.D. for the smaller section containing the contraceptive.”
Kiser is a faculty member in the department of biomedical engineering at the McCormick School of Engineering and Applied Science and in the department of obstetrics and gynecology at Northwestern University Feinberg School of Medicine.
The ring is easily inserted in the vagina and stays in place for three months. And because the tenofovir is delivered at the site of transmission, the ring — known as the tenofovir levonorgestrel IVR — utilizes a smaller dose than pills. The levonorgestrel released by the ring is the same drug as that used in certain contraceptive pills and in an intrauterine device.
“This system represents a significant advance in vaginal drug delivery technology and is the first in a new class of long-acting multipurpose prevention drug delivery systems,” say the authors in the study. They also report details of the ring’s engineering, safety, stability and drug release.
“The differences between the two drugs are huge, which presented us with a design challenge,” Kiser said. “Tenofovir is highly water soluble while levonorgestrel is highly water insoluble. And the daily dose is different: the ring delivers about 10 milligrams of tenofovir and only 10 micrograms of levonorgestrel. Our scientific hurdle was finding a way to manufacture a dual-purpose ring that got the device into the clinic.”
Tenofovir is taken orally by 3.5 million HIV-infected people worldwide, and it also has been studied as a gel. The drug inhibits HIV and HSV-2 (herpes simplex virus-2) replication in susceptible cells.
Previous studies have demonstrated that antiretroviral drugs can prevent HIV infection, but existing methods for delivering the drug fall short. Pills must be taken daily and require high doses; some women may prefer a longer-lasting method, such as the ring, versus methods used at the time of sex, such as a gel.
Kiser’s combination ring promises much more. The strength of the device stems from its unique polymer construction: its elastomer swells in the presence of fluid (such as that found in the human body), delivering up to 100 times more of the tenofovir than current intravaginal ring technology, which have release rates that decline over time.
“Products only work when they are used,” said co-author David Friend, product development director at CONRAD, which develops reproductive health technologies for low-income countries and is affiliated with Eastern Virginia Medical School.
“By having a ring that can remain in the body for up to 90 days, our hope is that this ring will offer a solution to increase adherence, and therefore provide greater protection against HIV while also preventing pregnancy,” he said.
The Latest on: Birth control
via Google News
The Latest on: Birth control
- Use Of Birth Control As A Teen Linked To Depressionon December 1, 2019 at 11:22 pm
From the color of tongue to changes around the mouth, read on to know the easy ways to detect iron deficiency. A key insight uncovered by researchers from Harvard might lead to the development of ...
- Is taking birth control as a teen linked to depression? It’s complicatedon December 1, 2019 at 3:25 am
“Does the pill cause depression?” the news headline asked. Prompted by a recent study that described a link between taking birth control pills as a teenager and depression in adulthood, the news got ...
- The Pill Can Make You Less Attracted to Jerks, and Other Surprising Facts About Birth Controlon November 29, 2019 at 8:38 pm
It’s served its purpose of preventing pregnancy, but do you really know what it’s done beyond that? You might want to pick up a copy of This Is Your Brain on Birth Control, a new book by Sarah E. Hill ...
- Doctors go to TikTok to talk to teens about vaping, birth control and how celery juice won't cure canceron November 29, 2019 at 5:00 pm
Doctors are starting to use TikTok to talk to teens and young adults about health issues that matter to them. That includes vaping, birth control and medical misinformation. They're gaining huge ...
- Male Birth Control Shot Reportedly Passes Clinical Trialson November 26, 2019 at 3:04 pm
The Indian Council of Medical Research (ICMR) has successfully completed clinical trials of the world’s first injectable male contraceptive, according to researchers involved in the project, reports ...
- I Tried Basal Body Temping: Why I’ll Never Go Back to Hormonal Birth Controlon November 26, 2019 at 1:03 pm
It was the tool I needed to feel some control while trying to conceive, and now it’s my preferred birth control. Share on Pinterest I had no idea what basal body temping (BBT) was until I was about 5 ...
- What happens if you stop taking birth control pills mid pack?on November 26, 2019 at 10:14 am
A person can stop taking birth control pills at any point, including during the middle of the pack. However, coming off birth control pills increases the likelihood of pregnancy in the absence of ...
- Common Myths Surrounding Birth Control Dispelled For Youon November 25, 2019 at 4:04 am
Here, we will bust some of the common myths surrounding birth control. Read on to know about them. Though it is rare for lactating mothers to become pregnant, possibilities are there. During ...
- Male Birth Control Shot Reportedly Passes Clinical Trials And Could Be Available As Early As 2020on November 21, 2019 at 3:07 pm
Ladies, rejoice! Male birth control is coming sooner than you think. Here’s what we know: There’s reportedly a new male contraceptive has completed clinical trials. It’s an injection into the groin ...
- Male birth control injected into the groin could be available next yearon November 21, 2019 at 10:45 am
A male birth control injected into the groin could be made available in the next year, Indian scientists say. The birth control successfully completed an Indian clinical trial recently and found a “97 ...
via Bing News